RIOK1 and neoplasm: Despite our de-validation of MTAP as a biomarker, that predicts cellular sensitivity to RIOK1 inhibition, other molecular alterations of tumor cells might sensitize cancer cells to the inhibition of RIOK1 kinase activity.